Hormones and Cancer

, Volume 1, Issue 2, pp 112–115 | Cite as

Treatment of Recurrent Endometrial Stromal Sarcoma with Letrozole: A Case Report and Literature Review

  • Vonetta T. Sylvestre
  • Charles J. Dunton


Endometrial stromal sarcomas are rare tumors that recur long after initial excision. We report a case of recurrent endometrial stromal sarcoma treated with the aromatase inhibitor letrozole and an overview of research completed to date. A 59-year-old female presented with new abdominal onset pain, fatigue, and nausea. She had a computed tomography that showed a pelvic mass, an enlarged right internal iliac lymph node, an atypical liver hemangioma, and a severe left hydronephrosis. The patient underwent an exploratory laparotomy, and attempted surgical resection of the pelvic mass was attempted. Pathology was consistent with recurrent endometrial stromal sarcoma. Since these tumors are hormonally sensitive, the patient was started on letrozole 2.5 mg daily. The patient had complete clinical and radiographic response by 11 months. After 24 months of therapy, the patient remained free of disease. Endometrial stromal sarcomas are hormonally sensitive tumors. Progestins function to decrease the effects of estrogen on target cells and have been used for primary therapy of endometrial stromal sarcomas. Aromatase inhibitors block peripheral synthesis of estrogen. Letrozole is a type 2 aromatase inhibitor that effectively reduces serum estrogen levels. Letrozole has been described as treatment for endometrial stromal sarcoma. Letrozole is well tolerated and is a good option for long-term management of this disease.


Endometrial stromal sarcoma Letrozole Progestins Aromatase inhibitors 


Conflicts of interest

The authors report no conflicts of interest.


  1. 1.
    Boutselis JG, Ullery JC (1962) Sarcoma of the uterus. Obstet Gynecol 20(1):23–35CrossRefPubMedGoogle Scholar
  2. 2.
    Harlow BW, Weiss NS, Lofton S (1986) The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76:399–402PubMedGoogle Scholar
  3. 3.
    Koss LG, Spiro RH, Brunschwig A (1965) Endometrial stromal sarcoma. Surg Gynecol Obstet 121:531–537PubMedGoogle Scholar
  4. 4.
    Moinfar F, Masood A, Tavassoli FA (2007) Uterine sarcomas. Path 39(1):55–71CrossRefGoogle Scholar
  5. 5.
    Brown L (2008) Pathology of uterine malignancies. Clin Oncol 20:433–447CrossRefGoogle Scholar
  6. 6.
    Katz L et al (1987) Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol 26:87–97CrossRefPubMedGoogle Scholar
  7. 7.
    Pink D et al (2006) Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 101:464–469CrossRefPubMedGoogle Scholar
  8. 8.
    Chu MC et al (2003) Low-grade stromal sarcoma: hormonal aspects. Gynecol Oncol 90:170–176CrossRefPubMedGoogle Scholar
  9. 9.
    Reich O, Regauer S (2007) Hormonal therapy of endometrial stromal sarcoma. Cur Opin in Oncol 19:347–352CrossRefGoogle Scholar
  10. 10.
    Ramondetta L et al (2009) Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade stromal sarcoma. Cancer 115:1867–1874CrossRefPubMedGoogle Scholar
  11. 11.
    Van Look P, von Hertzen H (1995) Clinical uses of antiprogestogens. Hum Repro Update 1(1):19–34CrossRefGoogle Scholar
  12. 12.
    Spitz IM, Bardin CW (2003) Mifepristone (RU 486)—a modulator of progestin and glucocorticoid action. New Engl J Med 329:404–412CrossRefGoogle Scholar
  13. 13.
    Reich O, Regauer S (2004) Aromatase expression in low-grade stromal sarcomas: an immunohistochemical study. Mod Path 17:104–108CrossRefGoogle Scholar
  14. 14.
    Reich O, Regauer S (2005) Hormonal therapy with aromatase inhibitors for patients with endometrial stromal sarcoma. Letter Gynecol Oncol 98(1):173–174CrossRefGoogle Scholar
  15. 15.
    Spano JP et al (2003) Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol 20(1):87–93CrossRefPubMedGoogle Scholar
  16. 16.
    Gadduci A, Cosio S, Genazzani AR (2004) Use of estrogen antagonist and aromatase inhibitors in breast cancers and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs 5(10):1031–1044Google Scholar
  17. 17.
    Lamb HM, Adkins JC (1998) Letrozole: a review of its use in postmenopausal women with advanced breast cancer. Drugs 56(6):1125–1140CrossRefPubMedGoogle Scholar
  18. 18.
    Dowsett M et al (1995) In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511–1515PubMedGoogle Scholar
  19. 19.
    Krauss K et al (2007) Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole. Anticancer Res 27:3477–3480PubMedGoogle Scholar
  20. 20.
    Leunen M et al (2004) Low grade stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 95:796–771CrossRefGoogle Scholar
  21. 21.
    Maluf FC et al (2001) Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 82:384–388CrossRefPubMedGoogle Scholar
  22. 22.
    Smith IE, Dowsett M (2003) Aromatase inhibitors and breast cancer. New Engl J Med 348:2431–2442CrossRefPubMedGoogle Scholar
  23. 23.
    Abdulhaq H, Geyer C (2008) Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Amer J Clin Oncol 31(6):595–605CrossRefGoogle Scholar
  24. 24.
    National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DCGoogle Scholar
  25. 25.
    Osteoporosis (2004) ACOG practice bulletin no. 50. American College of Obstetricians and Gynecologists, Washington DCGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyMontgomery HospitalNorristownUSA
  2. 2.Division of Gynecologic OncologyLankenau HospitalWynnewoodUSA
  3. 3.Lankenau HospitalLankenau Institute for Medical ResearchWynnewoodUSA

Personalised recommendations